Form D · Other

Fairfield Bio, Inc.

Bronx, NY · CIK 0002110597

Offering snapshot reported Oct 6, 2026 · SEC filing

Reported sold
$1.95M
Offering amount: $3M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 26, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$973K$1.95MFeb 12, 2026: $450,000.00Feb 12, 2026Oct 6, 2026: $1,945,000.00Oct 6, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$450,000 → $1,945,000
  • Reported investors1 → 11

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 6, 2026Amendment$1,945,000$1,495,000vs Feb 12, 202611SEC filing
Feb 12, 2026Initial$450,000No comparison1SEC filing

Offering details

Securities
Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-573452

Source: Form D, filed Oct 6, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kevin Slavin Director, Executive
Mitchell Wolfe Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
5454 Palisade Avenue
Bronx, NY, 10471